New drug trial targets rare, debilitating protein disease

NCT ID NCT06649695

Recruiting now Disease control Sponsor: European Myeloma Network B.V. Source: ClinicalTrials.gov ↗

Summary

This study is testing an experimental drug called teclistamab for people with AL amyloidosis who have already tried other treatments. The drug works by helping the immune system target and destroy the abnormal plasma cells that produce harmful proteins. Researchers want to see if this approach can effectively control the disease in 30 participants who have specific types of organ involvement.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU Limoges
NOT_YET_RECRUITING

Limoges, France

Contact
Fondazione I.R.C.C.S Policlinico "San Matteo"
NOT_YET_RECRUITING

Pavia, Italy

Contact
General Hospital of Athens "Alexandra"
RECRUITING

Athens, Greece

Contact
Paris St Louis
NOT_YET_RECRUITING

Paris, France

Contact
South Australia Health
NOT_YET_RECRUITING

Adelaide, Australia

Contact
UMC Utrecht
RECRUITING

Utrecht, Netherlands

Contact
University Hospital Essen
RECRUITING

Essen, Germany

Contact
University Hospital Heidelberg
RECRUITING

Heidelberg, Germany

Contact
University Hospital Würzburg
NOT_YET_RECRUITING

Würzburg, Germany

Contact
Westmead Hospital
RECRUITING

Sydney, Australia

Contact

Conditions

Explore the condition pages connected to this study.

AL AMYLOIDOSIS